azd0780 + ethinyl estradiol + levonorgestrel

AZD0780 + ethinyl estradiol + levonorgestrel is a theoretical combination drug comprising three distinct active ingredients: - **AZD0780**: an investigational oral small molecule PCSK9 inhibitor in development for the reduction of LDL cholesterol in patients with hypercholesterolemia, particularly those not meeting guideline targets on standard statin therapy. It acts by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), enhancing LDL receptor recycling and increasing clearance of LDL cholesterol from the bloodstream[1][2][3][4][5][6]. - **Ethinyl estradiol**: a synthetic estrogen most commonly used in combination oral contraceptives, with mechanisms including suppression of ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis. - **Levonorgestrel**: a synthetic progestin, often combined with ethinyl estradiol in hormonal contraception, acting primarily by suppressing ovulation and altering cervical mucus and endometrial lining to prevent pregnancy. The combination listed (AZD0780 + ethinyl estradiol + levonorgestrel) does not exist as a commercially available or clinically trialed product. There are no records or references to clinical development, approval, or trials of this specific triple-combination for any disease. AZD0780 is in phase III studies as monotherapy or with statins for cholesterol management; ethinyl estradiol and levonorgestrel are approved in numerous contraceptive products, but not in combination with AZD0780.